Für eine unvergessliche Reise – finden Sie Top-Touren und Aktivitäten an Ihrem Urlaubsort. Buchen Sie mit einem sicheren Gefühl. Kostenlose Stornierung bis zu 24 Stunden vor Beginn.
Startseite:
- Tagesausflüge
Ein Tag, tausende Möglichkeiten.
Tagestrip nach Verona buchen
- BESTE Tagesausflüge
Die besten Tagesausflüge in
Verona.-Jetzt vergleichen und...
Suchergebnisse
Suchergebnisse:
The Verona Trial (Italian: processo di Verona) was a show trial held in January 1944 in the Italian Social Republic (RSI) to punish the 19 members of the Grand Council of Fascism who had voted for Benito Mussolini's removal from power in the Kingdom of Italy. Six of them had been captured by Mussolini's forces and were present for ...
28. Mai 2021 · To confirm these benefits, the VERONA study, a randomized, double-blind, phase 3 study (NCT04401748) of patients with treatment-naïve HR-MDS, will assess the safety and efficacy of Ven combined with Aza including CR rate and overall survival.
- Amer Methqal Zeidan, Jacqueline Suen Garcia, Pierre Fenaux, Uwe Platzbecker, Yasushi Miyazaki, Zhi-J...
- 2021
2. Sept. 2022 · The ongoing phase 3 VERONA study (NCT04401748) seeks to evaluate whether the addition of venetoclax to azacitidine improves overall survival in patients with high-risk myelodysplastic syndromes. This drug combination has the potential to establish a new standard of care in this patient population.
12. Aug. 2020 · This confirmatory trial (VIALE-A) was designed to evaluate the efficacy and safety of the azacitidine–venetoclax combination regimen as compared with a control regimen of azacitidine and...
- Courtney D DiNardo, Brian A Jonas, Vinod Pullarkat, Michael J Thirman, Jacqueline S Garcia, Andrew H...
- 2020
26. Mai 2020 · Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona)
9. Dez. 2022 · The randomized phase 2 SWOG S1117 trial compared standard-of-care azacitidine with azacitidine in combination with either lenalidomide or vorinostat in 277 patients with HR-MDS. 12 This trial showed an overall response rate (ORR) of 38% in the azacitidine group with no significant improvement in ORR in the combination groups.
Within 60 days after study start, 7 deaths (6.5%) were reported. Conclusion: Ven 400 mg for 14 days plus Aza combination was well tolerated with favorable responses of CR+PR+mCR in >80% and HI in nearly 50% of patients with treatment-naïve HR MDS.
